A Retrospective Chart Review Study of Real-World Use of Talimogene Laherparepvec in Unresectable Stage  IIIB–IVM1a Melanoma in Four European Countries

ConclusionThis study is the first comprehensive multinational evaluation of the use of T-VEC to treat unresectable stage  IIIB/C–IVM1a melanoma in real-world clinical practice in Europe. The differences between European countries were apparent, with physicians in the Netherlands using T-VEC in patients with earlier advanced disease stage and in the first-line setting compared with other countries.
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research